GLOW (70mg Blend) Dosage Protocol
Three-peptide repair blend — GHK-Cu + TB-500 + BPC-157 in one 70 mg vial; the combination is not clinically validated.
Why GLOW draws research interest
These are the directions researchers and the peptide community most often explore GLOW for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.
Tissue repair & recovery
The reason most people look up GLOW: its BPC-157 and TB-500 components are studied for tissue repair in preclinical animal models only.
Skin & collagen
GHK-Cu, the copper peptide in this blend, is researched in cosmetic and skin studies for collagen and extracellular-matrix support.
Anti-inflammatory pathways
Each component is investigated in preclinical research for inflammation-related signaling; none is an approved anti-inflammatory therapy.
Combination-blend interest
People also search GLOW to understand how three peptides in one 70 mg vial compare, though the combination itself is not clinically validated.
Research context, not medical advice. Nothing here says GLOW treats, cures, or improves any condition. Evidence ranges from early laboratory work to clinical trials depending on the use — the sections below cover the actual data and sources.
Mix & measure GLOW · 70 mg
Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers.
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →
Quickstart Highlights
GLOW is a research three-peptide blend — GHK-Cu, TB-500 (a Thymosin Beta-4 fragment) and BPC-157 — supplied together in a single 70 mg vial. Each component has been studied separately for tissue-repair-related activity in preclinical and cell models[1][5]. This page outlines a once-daily subcutaneous approach for the combined vial. The idea that the three act “synergistically” is a marketing hypothesis, not validated in any human trial; none of the three peptides is FDA-approved, and the blend is presented for research and educational use only.
Add 3.0 mL bacteriostatic water to the one combined 70 mg vial → ~23.3 mg/mL total blend (1 unit ≈ 233 mcg total).
2,330 mcg (2.33 mg) total blend once daily for 4 weeks, then a 2–4 week break before any repeat cycle.
At ~23.3 mg/mL, 1 unit ≈ 233 mcg total; the daily 2,330 mcg dose is 10 units (0.10 mL) on a U-100 syringe.
Lyophilized: store at −20 °C (−4 °F); once reconstituted, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the solution.
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.
Dosing & Reconstitution Guide
A single practical dilution with accurate once-daily dosing, step by step
Standard Approach (3 mL = ~23.3 mg/mL total blend)
Reconstitute: Add 3.0 mL bacteriostatic water to the combined 70 mg vial → final concentration ~23.3 mg/mL total blend.
Typical daily dose: 2,330 mcg (2.33 mg) total blend once daily for 4 weeks, then 2–4 weeks off.
Easy measuring: At ~23.3 mg/mL, 1 unit ≈ 233 mcg total on a U-100 syringe. The daily 2,330 mcg dose is 10 units (0.10 mL); units = total mcg ÷ 233.
Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the mixed solution.
Frequency: one subcutaneous injection each day at a fixed 2,330 mcg total-blend dose for 4 weeks, followed by a 2–4 week off period before any repeat cycle[3][4]. This schedule and the split between the three peptides come from the product’s own materials, not from approved human dosing.
Per-component split (inferred): the page does not state how many mg of each peptide are loaded in the 70 mg vial. Applying the product’s stated 5:1:1 ratio to each 2,330 mcg dose implies roughly 1.67 mg GHK-Cu + 0.33 mg TB-500 + 0.33 mg BPC-157 per injection. These are inferred from the ratio, not confirmed vial contents, and they sum to ~2.36 mg versus the 2.33 mg stated (rounding).
Reconstitution Steps
Draw 3.0 mL of bacteriostatic water into a sterile syringe.
Release it slowly down the vial’s inner wall to limit foaming.
Swirl or roll gently until fully dissolved — don’t shake.
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
At 23.3 mg/mL the daily dose reads at 10 units (0.10 mL); for a small volume like this, a 30- or 50-unit insulin syringe improves readability. Avoid freezing the reconstituted solution, since freeze–thaw can denature the peptides.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Quantities below assume a 4-week course of once-daily injections at the standard 2,330 mcg total-blend dose.
One 70 mg combined vial covers the full 4-week (28-day) daily protocol at standard dosing.
- 4 weeks (28 days): 1 vial
- Per injection: 1 syringe
- 4 weeks (once daily): 28 syringes
Use 3.0 mL per 70 mg vial for reconstitution.
- 4 weeks (1 vial): 3 mL → 1 bottle
One for the vial stopper + one for the injection site each day.
- Per injection: 2 swabs
- 4 weeks (once daily): 56 swabs → 1 box (100-count)
Protocol Overview
A concise summary of the once-daily regimen, drawn from commonly cited reference protocols.
- ▪Goal: Combine three repair-associated peptides (GHK-Cu, TB-500, BPC-157) aimed at tissue repair, angiogenesis and inflammation — effects reported only in preclinical/cell models, with the 3-peptide synergy unvalidated in humans[5][6].
- ▪Schedule: Daily subcutaneous injections for 4 weeks, then a 2–4 week off period before any repeat cycle.
- ▪Daily Dose: 2,330 mcg (2.33 mg) total blend once daily = 10 units (0.10 mL).
- ▪Reconstitution: 3.0 mL bacteriostatic water per 70 mg vial gives ~23.3 mg/mL total blend (1 unit ≈ 233 mcg).
- ▪Storage: Keep the dry vial frozen at −20 °C (−4 °F); once mixed, refrigerate at 2–8 °C and do not freeze the solution.
Dosing Protocol
A fixed-dose daily approach based on the product’s own materials.
- ▪Dose: 2,330 mcg total blend once daily (10 units / 0.10 mL); units = total mcg ÷ 233.
- ▪Per-injection split (inferred): at the stated 5:1:1 ratio, ~1.67 mg GHK-Cu + 0.33 mg TB-500 + 0.33 mg BPC-157 — inferred, not confirmed vial contents.
- ▪Hold: Keep the dose constant across all 4 weeks rather than titrating.
- ▪Cycle Length: 4 weeks on, then 2–4 weeks off before any repeat cycle.
- ▪Timing: Inject at a consistent time each day and rotate injection sites systematically.
Storage Instructions
Correct storage is what preserves the peptide’s stability and activity.
- ▪Lyophilized: Hold the dry vial at −20 °C (−4 °F) in dry, dark conditions and limit moisture exposure[7].
- ▪Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within about 28 days; do not freeze the mixed solution, as freezing can denature peptides[8].
- ▪Handling: Let frozen vials warm to room temperature before opening so condensation won’t form, and keep the solution clear of heat and direct light.
- ▪Freeze–thaw: Avoid repeated freeze–thaw cycles of the reconstituted solution.
Important Notes
Practical points that keep daily administration safe and consistent.
- ▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward.
- ▪Site rotation: Move between abdomen, thighs and upper arms to reduce local irritation and lipohypertrophy[9].
- ▪Slow injection: Push the plunger slowly and pause a few seconds before withdrawing the needle to prevent backflow.
- ▪Recordkeeping: Log the daily dose, injection site and any observations to keep the protocol consistent.
- ▪Regulatory note: Both TB-500 and BPC-157 are prohibited by WADA (treat the whole blend as banned for athletes); GHK-Cu, TB-500 and BPC-157 are all unapproved research chemicals, none FDA-approved for human administration[10].
How This Works
GLOW packs three different repair-associated peptides into one 70 mg vial. Each has its own proposed mechanism, drawn almost entirely from cell-culture and animal models — none is established in humans.
GHK-Cu (copper tripeptide): a copper-binding tripeptide studied for roles in collagen synthesis, angiogenesis and anti-inflammatory signalling[1]. Topical GHK-Cu is used as a cosmetic ingredient, but injectable GHK-Cu is not approved.
TB-500 (Thymosin Beta-4 fragment): a synthetic peptide reproducing the active region of Tβ4. Its proposed mechanism centres on G-actin sequestering, cell migration and angiogenesis in preclinical work[5][6]. No completed human efficacy trial of the fragment exists.
BPC-157 (gastric peptide): a synthetic sequence derived from a gastric protein, studied in animals for soft-tissue and tendon repair[11]. Human evidence is anecdotal.
Important caveat: the claim that combining the three produces synergistic repair is a marketing hypothesis — it has never been tested in a human trial, and no clinical data validate the specific 70 mg three-peptide combination.
GHK-Cu, TB-500 and BPC-157 are all unapproved research chemicals — none is FDA-approved (2026 compounding activity is not approval). The blend is presented here for research and educational purposes only.
Lifestyle Factors
Habits that may support recovery alongside the protocol.
- ▪Nutrition: Keep protein intake adequate to give tissue repair the building blocks it needs.
- ▪Activity & rest: Pair appropriate movement with real recovery time and avoid overtraining during an injury-recovery phase.
- ▪Sleep: Aim for 7–9 hours to support the body’s natural repair processes.
- ▪Stress: Manage stress with evidence-based practices, since it influences overall healing.
Potential Benefits & Side Effects
What preclinical and veterinary literature describe; human evidence is limited and individual results vary.
Potential Benefits
- ▪Wound healing (preclinical): Animal studies report faster wound healing and tissue repair via enhanced angiogenesis and cell migration[5][6].
- ▪Inflammation & fibrosis (preclinical): Thymosin pathways have been linked to reduced inflammation and fibrosis in animal models[11].
- ▪Tolerability (veterinary): Generally well tolerated in veterinary studies, with occasional mild injection-site reactions.
- ▪Note on humans: These benefits are not established in humans — no large-scale clinical trials of the TB-500 fragment have been completed[13].
Common Side Effects
- ▪Injection-site reactions: Mild redness, tenderness or soreness can occur; rotating sites helps.
- ▪Unknown long-term profile: Human safety data is limited, so caution and monitoring are advised.
- ▪Sport restriction: Both TB-500 and BPC-157 are WADA-prohibited, so treat the GLOW blend as banned for athletes.
Injection Technique
General subcutaneous technique, following established clinical best-practice guidance[14][15].
Pre-Injection Preparation
- ▪Wash your hands well with soap and water.
- ▪Wipe the vial stopper with an alcohol swab and let it air-dry.
- ▪Choose a site (abdomen, thigh, or upper arm) and clean it with a fresh alcohol swab, letting it dry fully[15].
- ▪Draw the intended dose, then check for air bubbles and push any out.
Injection Procedure
- ▪Pinch a skinfold at the chosen site between thumb and forefinger.
- ▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[14].
- ▪Skip aspiration for subcutaneous shots — it isn’t needed[14].
- ▪Press the plunger slowly and steadily until it’s fully down.
- ▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
Post-Injection Care
- ▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle.
- ▪Return the reconstituted vial to the fridge right away.
- ▪Rotate the injection site each day to prevent irritation and lipohypertrophy[9].
- ▪Watch the site for excess redness, swelling, or signs of infection.
Recommended Source
For high-purity research peptides, we point researchers to Prime Lab Peptides for the GLOW 70 mg three-peptide blend.
Why Prime Lab Peptides?
- ▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA.
- ▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
- ▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
- ▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
- ▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
References
- 1
FASEB JournalBiological activities of thymosin beta-4 mapped to active peptide sequences, including the fragment marketed as TB-500.
- 2
Journal of Chromatography A (PubMed)Doping-control analysis of TB-500 as a synthetic thymosin beta-4 fragment in biological samples.
- 3
WADA Scientific ResearchInvestigation of TB-500 metabolism, synthesis of its metabolites, and detection limits.
- 4
Racing Medication & Testing ConsortiumThymosin beta-4 regulatory bulletin covering TB-500 use in equine sports medicine.
- 5
Journal of Investigative Dermatology (PubMed)Thymosin beta-4 accelerates wound healing in a preclinical model.
- 6
FASEB Journal (PubMed)Active-site mapping of thymosin beta-4 fragments for angiogenesis and cell migration.
- 7
Peptide Storage GuideBest practices for storing lyophilized peptides (temperature, humidity and light protection).
- 8
Bacteriostatic Water GuidanceBacteriostatic water for injection: multi-dose vial stability and handling.
- 9
NCBI BookshelfBest practices for subcutaneous injection: aseptic technique and site rotation.
- 10
WADA Prohibited ListClassification of TB-500 as a prohibited substance in competitive sport.
- 11
Journal of Investigative DermatologyThymosin beta-4 wound-healing mechanisms: collagen deposition, angiogenesis and granulation tissue.
- 12
Journal of Chromatography B (PubMed)Quantification of TB-500 metabolites and screening of wound-healing activity (prodrug hypothesis).
- 13
ClinicalTrials.govTrial registry for full-length thymosin beta-4 (e.g., dermal and ocular indications); no completed efficacy trials of the TB-500 fragment.
- 14
Centers for Disease Control and Prevention (CDC)Subcutaneous injection technique: angle, site and no-aspiration guidance.
- 15
Subcutaneous Injection Technique (Patient Education)How to administer a subcutaneous injection: clinical technique guidelines.
- 16
Prime Lab PeptidesGLOW 70 mg blend (GHK-Cu + TB-500 + BPC-157) product page — purity specifications and certificates of analysis.
How to reconstitute GLOW
- 1Wipe the vial stopper and your bacteriostatic-water vial with an alcohol swab.
- 2Draw your chosen amount of bacteriostatic water and inject it slowly down the inner wall of the GLOW vial.
- 3Let it rest, then gently swirl until fully dissolved — do not shake.
- 4Refrigerate the reconstituted vial and draw each dose with a U-100 insulin syringe.
GLOW — frequently asked questions
How do I reconstitute a 70 mg vial of GLOW?
Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units.
How much bacteriostatic water should I add to GLOW?
There is no single correct amount — more water simply spreads the same 70 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units.
What do the "units" on an insulin syringe mean?
On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand.
How should I store GLOW after mixing?
Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product.
How many doses does a 70 mg vial of GLOW provide?
Divide the vial strength of 70 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose.
Is GLOW approved for human use?
No. GLOW is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.
New protocols & dosing updates
Reconstitution charts, new peptide protocols and safety updates — straight to your inbox. No spam, unsubscribe anytime.